Anthropic Adds Novartis CEO Vas Narasimhan to Its Board—and That’s a Bigger Deal Than It Sounds

Anthropic just made a board appointment that actually makes sense if you think about it for more than a minute.

Vas Narasimhan, the CEO of Novartis and a physician-scientist by training, is joining Anthropic’s Board of Directors. He was appointed by the company’s Long-Term Benefit Trust—that independent body with no financial stake in Anthropic, whose entire job is to keep the company honest about balancing profit with its public benefit mission.

This isn’t just another tech company grabbing a pharma exec for optics. Narasimhan has overseen the development and approval of more than 35 novel medicines. That’s not easy in one of the most heavily regulated industries on the planet. Daniela Amodei put it well: “Getting powerful new technology to people safely and at scale is what we think about every day at Anthropic. Vas has been doing exactly that for years.”

She’s not wrong. Most AI safety discussions stay theoretical. Narasimhan has actually navigated the real-world mess of bringing breakthrough science through regulatory hurdles and into people’s hands. That experience is rarer than you’d expect on AI boards.

What’s more interesting is the governance angle. With Narasimhan’s appointment, Trust-appointed directors now make up a majority of Anthropic’s board. That’s a structural choice that matters. The Trust exists specifically to prevent the kind of mission drift that happens when growth pressures take over. Having a majority of directors who don’t have a financial stake in the company is unusual and, frankly, a hedge against the standard Silicon Valley trajectory where “move fast and break things” becomes “move fast and break governance.”

Narasimhan joins a board that already includes Dario Amodei, Daniela Amodei, Yasmin Razavi, Jay Kreps, Reed Hastings, and Chris Liddell. It’s a mix of tech, finance, and now hard-won experience in regulated science.

Early in his career, Narasimhan worked on HIV/AIDS, malaria, and tuberculosis programs in India, Africa, and South America. He’s an elected member of the US National Academy of Medicine and serves on the University of Chicago board of trustees. This isn’t someone who just runs a big company—he’s been in the trenches on global health access.

The healthcare angle is worth watching. Anthropic has been pushing into medical applications, and having a board member who understands both the science and the regulatory landscape could accelerate that work. AI in healthcare has a lot of hype, but the real bottlenecks are often about safety, validation, and deployment at scale—exactly what Narasimhan has been dealing with.

I’m curious to see how this plays out. Board appointments at AI companies tend to be either rubber stamps or celebrity grabs. This one feels different. It signals that Anthropic is serious about the “public benefit” part of its Public Benefit Corporation structure, and that it understands the value of people who have actually shipped safe technology in complex environments.

Whether that translates into better products and fewer safety incidents remains to be seen. But it’s a step in the right direction.